Continued up and down performance for the market into the week ending January 19th. Sanofi jumped into the M&A game with a $1.7B acquisition of Inhibrx:
Week Ending January 19th, 2024
Biotech: 6 Transactions (6 Follow-Ons) totaling just over $800 Million
Med Tech: No Current Week Transactions
2024 YTD:
18 Biotech transactions totaling just under $3 Billion v. 2023: 4 Biotech transaction totalings just under $600 Million
1 Med Tech transaction totaling $50 Million v. 2023: 0 Med Tech transactions
Private Transactions:
Biotech: 13 US Transactions / 9 European Transactions
Med Tech: 9 US Transactions / 4 European Transaction
M&A Deals:
Sanofi acquired Inhibrx for $1.7B or $30/share
Comments